Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer

被引：199

作者：

Asim, Mohammad ^{[1
,2
]}

Tarish, Firas ^{[3
,4
]}

Zecchini, Heather I. ^{[1
]}

Sanjiv, Kumar ^{[3
]}

Gelali, Eleni ^{[3
]}

Massie, Charles E. ^{[1
]}

Baridi, Ajoeb ^{[1
]}

Warren, Anne Y. ^{[5
]}

Zhao, Wanfeng ^{[5
]}

Ogris, Christoph ^{[3
]}

McDuffus, Leigh-Anne ^{[1
]}

Mascalchi, Patrice ^{[1
]}

Shaw, Greg ^{[1
]}

Dev, Harveer ^{[1
]}

Wadhwa, Karan ^{[1
]}

Wijnhoven, Paul ^{[6
]}

Forment, Josep V. ^{[6
]}

Lyons, Scott R. ^{[1
]}

Lynch, Andy G. ^{[1
]}

O'Neill, Cormac ^{[1
]}

Zecchini, Vincent R. ^{[1
]}

Rennie, Paul S. ^{[7
]}

Baniahmad, Aria ^{[8
]}

Tavare, Simon ^{[1
]}

Mills, Ian G. ^{[9
,10
]}

Galanty, Yaron ^{[6
]}

Crosetto, Nicola ^{[3
]}

Schultz, Niklas ^{[3
]}

Neal, David ^{[1
,11
]}

Helleday, Thomas ^{[3
]}

机构：

[1] Univ Cambridge, Canc Res UK Inst, Li Ka Shing Ctr, Cambridge CB2 0RE, England

[2] Univ Surrey, Dept Clin & Expt Med, Guildford GU2 7WG, Surrey, England

[3] Karolinska Inst, Dept Med Biochem & Biophys, Div Translat Med & Chem Biol, Sci Life Lab, S-17121 Stockholm, Sweden

[4] Cent Hosp Vasteras, Dept Urol, S-72189 Vasteras, Sweden

[5] Addenbrookes Cambridge Univ Hosp, Dept Pathol, Cambridge CB2 0QQ, England

[6] Univ Cambridge, Wellcome Trust & Canc Res UK Gurdon Inst, Cambridge CB2 1QN, England

[7] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC V6H 3Z6, Canada

[8] Jena Univ Hosp, Inst Human Genet, D-07743 Jena, Germany

[9] Univ Oslo, Ctr Mol Med Norway, Nord European Mol Biol Lab Partnership, N-0318 Oslo, Norway

[10] Queens Univ, Prostate Canc UK Movember Ctr Excellence, Belfast BT9 7AE, Antrim, North Ireland

[11] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg, Headley Way, Oxford OX3 9DU, England

来源：

NATURE COMMUNICATIONS | 2017年 / 8卷

基金：

瑞典研究理事会;

关键词：

DNA-REPAIR; THERAPY; QUANTIFICATION; INHIBITION; POLYMERASE;

D O I：

10.1038/s41467-017-00393-y

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Emerging data demonstrate homologous recombination (HR) defects in castration-resistant prostate cancers, rendering these tumours sensitive to PARP inhibition. Here we demonstrate a direct requirement for the androgen receptor (AR) to maintain HR gene expression and HR activity in prostate cancer. We show that PARP-mediated repair pathways are upregulated in prostate cancer following androgen-deprivation therapy (ADT). Furthermore, upregulation of PARP activity is essential for the survival of prostate cancer cells and we demonstrate a synthetic lethality between ADT and PARP inhibition in vivo. Our data suggest that ADT can functionally impair HR prior to the development of castration resistance and that, this potentially could be exploited therapeutically using PARP inhibitors in combination with androgen-deprivation therapy upfront in advanced or high-risk prostate cancer.

引用

页数：10

共 30 条

[1] Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer
Al-Ubaidi, Firas L. T.
Schultz, Niklas
Loseva, Olga
Egevad, Lars
Granfors, Torvald
Helleday, Thomas
[J]. CLINICAL CANCER RESEARCH, 2013, 19 (06) : 1547 - 1556
[2] Annaratone L, 2017, ONCOTARGET, V8, P18680, DOI 10.18632/oncotarget.15727
[3] Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target
Asim, Mohammad
Massie, Charles E.
Orafidiya, Folake
Pertega-Gomes, Nelma
Warren, Anne Y.
Esmaeili, Mohsen
Selth, Luke A.
Zecchini, Heather I.
Luko, Katarina
Qureshi, Arham
Baridi, Ajoeb
Menon, Suraj
Madhu, Basetti
Escriu, Carlos
Lyons, Scott
Vowler, Sarah L.
Zecchini, Vincent R.
Shaw, Greg
Hessenkemper, Wiebke
Russell, Roslin
Mohammed, Hisham
Stefanos, Niki
Lynch, Andy G.
Grigorenko, Elena
D'Santos, Clive
Taylor, Chris
Lamb, Alastair
Sriranjan, Rouchelle
Yang, Jiali
Stark, Rory
Dehm, Scott M.
Rennie, Paul S.
Carroll, Jason S.
Griffiths, John R.
Tavare, Simon
Mills, Ian G.
McEwan, Iain J.
Baniahmad, Aria
Tilley, Wayne D.
Neal, David E.
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (05):
[4] Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
Attard, Gerhardt
Reid, Alison H. M.
A'Hern, Roger
Parker, Christopher
Oommen, Nikhil Babu
Folkerd, Elizabeth
Messiou, Christina
Molife, L. Rhoda
Maier, Gal
Thompson, Emilda
Olmos, David
Sinha, Rajesh
Lee, Gloria
Dowsett, Mitch
Kaye, Stan B.
Dearnaley, David
Kheoh, Thian
Molina, Arturo
de Bono, Johann S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) : 3742 - 3748
[5] BOSTWICK DG, 1994, AM J CLIN PATHOL, V102, pS38
[6] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, HE
Schultz, N
Thomas, HD
Parker, KM
Flower, D
Lopez, E
Kyle, S
Meuth, M
Curtin, NJ
Helleday, T
[J]. NATURE, 2005, 434 (7035) : 913 - 917
[7] PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination
Bryant, Helen E.
Petermann, Eva
Schultz, Niklas
Jemth, Ann-Sofie
Loseva, Olga
Issaeva, Natalia
Johansson, Fredrik
Fernandez, Serena
McGlynn, Peter
Helleday, Thomas
[J]. EMBO JOURNAL, 2009, 28 (17) : 2601 - 2615
[8] Molecular determinants of resistance to antiandrogen therapy
Chen, CD
Welsbie, DS
Tran, C
Baek, SH
Chen, R
Vessella, R
Rosenfeld, MG
Sawyers, CL
[J]. NATURE MEDICINE, 2004, 10 (01) : 33 - 39
[9] Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression
Cheng, Helen
Snoek, Rob
Ghaidi, Fariba
Cox, Michael E.
Rennie, Paul S.
[J]. CANCER RESEARCH, 2006, 66 (21) : 10613 - 10620
[10] Androgen suppression and radiation vs radiation alone for prostate cancer - A randomized trial
D'Amico, Anthony V.
Chen, Ming-Hui
Renshaw, Andrew A.
Loffredo, Marian
Kantoff, Philip W.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (03): : 289 - 295

← 1 2 3 →